Marian Rewers, MD, PhD is Professor of Pediatrics and Medicine at the University of Colorado School of Medicine. As the clinical director and the interim executive director of the Barbara Davis Center for Diabetes, he is leading the clinical team of 25 physicians/scientists and over 120 ancillary and research staff. The Barbara Davis Center serves more than 6,000 children and adults with type 1 diabetes (T1D). The Center is a major diabetes research institute with annual research funding of $19 million, mostly from NIH, JDRF and CDF.nnDr. Rewers is a graduate of the Academy of Medicine in Poznan, Poland, where he completed his residency in pediatrics before going to Pittsburgh as a fellow of the American Diabetes Association, in 1986. For the past 23 years, he has worked at the University of Colorado with the primary goal to prevent autoimmune diabetes by identifying and eliminating its environmental cause(s). He is the principal investigator of a prospective study – The Diabetes Autoimmunity Study in the Young (DAISY) – funded by the National Institutes of Health (NIH) continuously since 1993. DAISY screened for diabetes genes in 31,000 newborns from families free of diabetes as well as 1,800 young relatives of people with the disease. Over 2,500 high-risk infants have been followed until today to learn how genes and the environment interact to trigger the onset of T1D. Based on this model, the NIH funded The Environmental Determinants of Diabetes in the Young (TEDDY) consortium that includes centers from Colorado, Washington, Georgia/Florida, Germany, Finland, and Sweden. Dr. Rewers is heading the Colorado center as well as co-chairing the TEDDY Steering Committee. This is the most comprehensive effort ever to identify environmental triggers of T1D. TEDDY has screened over 424,000 newborns and intensively follows 8,677 of those with the highest risk genes. In the first population study of celiac disease in the United States, based on DAISY and funded since 1995, Dr. Rewers and his colleagues have dissected the occurrence of celiac disease in patients with T1D, their relatives, and in the general population. Leading the Colorado center of the Insulin Resistance Atherosclerosis Study (IRAS) and with his team from the Coronary Artery Calcification in Type 1 (CACTI) study, he has discovered a number of novel genetic, metabolic, and inflammatory factors of potential importance for prevention of diabetic complications. Dr. Rewers has been awarded over $2 million in research grants from JDRF for his novel and original research on T1D. Dr. Rewers has helped to train the next generation of investigators in clinical and translational research, including a number of pediatric endocrinologists. Together, they have published more than 300 original articles and reviews in the area of diabetes. In recognition of his research and clinical endeavors, Dr. Rewers has previously received the Michaela Modan Memorial Award and the Kelly West Award from the American Diabetes Association, and the University of Pittsburgh Kenny/Drash Award.nnThe JDRF’s prestigious Mary Tyler Moore and S. Robert Levine Award for Excellence in Clinical Research recognizes his important contributions in the area of prevention of childhood-onset T1D. The award ceremony will take place during the annual meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, on September 25.